Chitinase-like proteins (CLPs) are key immunosuppressive factors in various cancers, including triple-negative breast cancer (TNBC). Among these, chitinase 3-like 1 (CHI3L1) plays a prominent role in shaping an immunosuppressive tumor immune microenvironment (TIME) that supports tumor progression and impairs anti-tumor immunity. We here investigated CHI3L1 to dissect its individual contribution to TNBC by intraductally inoculating CHI3L1 knockout (KO) BALB/c mice with syngeneic 4T1 TNBC cells. Using flow cytometric immunophenotyping in combination with cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq), we assessed how host CHI3L1 deficiency affects tumor growth and the TNBC TIME. CHI3L1 KO mice exhibited significantly reduced primary tumor volumes compared to wild-type (WT) controls. In 4T1 primary tumors isolated from CHI3L1 KO mice, immunosuppressive innate cell populations, including polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), tumor-associated neutrophils (TANs), and M2-like macrophages, were significantly reduced. In marked contrast, CD4+ T cells, natural killer (NK), and NK-T cells were enriched in these primary tumors. CD8+ T-cells displayed an enhanced activation profile in the CHI3L1 KO TIME, based on decreased PD-1 and increased granzyme B, Ki67, and interferon-γ expression. CITE-seq on sorted CD45+ leukocytes confirmed these findings at the single cell level and revealed TANs to be the major source of CHI3L1 in 4T1 primary tumors from WT mice. Notably, immune checkpoint protein expression was diminished on tumor-associated macrophages (TAMs) in the CHI3L1 KO TIME, further indicating reduced immunosuppression. Gene set enrichment analysis (GSEA) of differentially expressed genes in our single cell immune atlas of the CD45+ TIME from both KO and WT mice showed significant downregulation of vesicle-mediated transport, suggesting at first that CHI3L1 may regulate immunosuppressive signaling via vesicular trafficking. These findings at the preclinical level identify TAN-derived CHI3L1 as a key immunosuppressive regulator in TNBC and indicate that targeting CHI3L1 in TNBC patients can have significant anti-tumor effects.